Fibrosis Chronic Articles & Analysis
9 news found
Reducing headcount by 50% to further extend capital resources Cash runway extended to at least mid-2024 Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the third quarter of 2022 and readout from part 2 of the study expected in the first quarter of 2023 Atopic Dermatitis Program will be delayed due to restructuring ...
ByBiomX
” About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. ...
ByBiomX
About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. ...
ByBiomX
(NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (“CF Foundation”). ...
ByBiomX
It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease which results in progressive and irreversible decline in lung function. ...
Addressing an Unmet Medical Need There is a great need for treatments targeting fibrosis related to Chronic Kidney Disease (CKD). Kidney fibrosis (KF) is a pathological hallmark of CKD and a major contributing factor to progression to end-stage CKD. ...
McCray’s team on the delivery of proteins to airway cells and in vivo models, aiming to advance new therapeutic avenues in the treatment of pulmonary diseases such as cystic fibrosis, asthma and chronic obstructive pulmonary disease (COPD). Researchers involved are experts in airway epithelial cells, pulmonary biology, lung diseases, as well as recombinant ...
” LTI-03 – Potential to Dramatically Improve Patient Health in IPF Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease with progressive scarring in the lungs from unknown causes such as disease, injury or genetics. ...
Abbott today awarded the 2010 Thriving Student Achiever Scholarship to Jason Egbert, a student with cystic fibrosis who demonstrates exceptional academic achievement, community service, creative and artistic talent and passion for inspiring others. Jason Egbert from Rexburg, Idaho, was selected for the Thriving Student Achiever Scholarship from a group of 40 outstanding students ...